

Uvisa Health ApS

CVR-nr.: 42444383

Boltonvej 21A
2300 København S

Annual report
7 June 2021 - 31 December 2021

**The annual report has been presented and
approved on the company's general meeting the**

25/05/2022

Ella Harris
Chairman of general meeting

Content

Company informations

Company informations

Management's Review

Management's Review

Financial statement

Income statement

Balance sheet

Disclosures

Company information

Reporting company Uvisa Health ApS
Boltonvej 21A
2300 København S

CVR-nr: 42444383
Reporting period: 07/06/2021 - 31/12/2021

Management's Review

Management's review

Principal activities

Conducting scientific research and validation of proposed solution. Assessing market and developing business model.

Development in activities and financial matters

Uvisa have continued to raise soft funding that has not diluted equity to other owners. We are still operating in the validation phase for the technology that we are developing and have no general operating costs in relation to staff or premises as we are supported by various incubator programs currently. Soft funding has predominantly been used for materials, services such as lab testing by a third party, and business plan development. As such we are operating at very low costs currently and have no revenue.

Events after the balance sheet date

No events materially affecting the Company's financial position have occurred subsequent to the financial year end.

Management considers the conditions for opting out of audit to be met.

Income statement 7 Jun 2021 - 31 Dec 2021

	Disclosure	2021
Revenue		kr. 0
External expenses		-39,131
Gross Result		-39,131
Employee expense		0
Depreciation, amortisation expense and impairment losses of property, plant and equipment and intangible assets		0
Profit (loss) from ordinary operating activities		-39,131
Other finance income		319,471
Other finance expenses		-681
Profit (loss) from ordinary activities before tax		279,659
Tax expense		-66,814
Profit (loss)		212,845
Proposed distribution of results		
Proposed dividend recognised in equity		0
Reserve for net revaluation according to equity method		0
Retained earnings		212,845
Proposed distribution of profit (loss)		212,845

Balance sheet 31 December 2021

Assets

	Disclosure	2021
		kr.
Goodwill		0
Intangible assets		0
Land and buildings		0
Plant and machinery		0
Fixtures, fittings, tools and equipment		0
Right of use assets		0
Property, plant and equipment		0
Investments in group enterprises		0
Investments in associates		0
Participating interests		0
Other investments		0
Contract assets		0
Investments		0
Total non-current assets		0
Raw materials and consumables		0
Manufactured goods and goods for resale		0
Inventories		0
Other receivables		192,608
Receivables		192,608
Other investments		0
Investments		0
Cash and cash equivalents		235,188
Current assets		427,796
TOTAL ASSETS		427,796

Balance sheet 31 December 2021

Liabilities and equity

	Disclosure	2021
		kr.
Contributed capital		40,000
Retained earnings		212,845
Total equity		252,845
Provisions for deferred tax		7,228
Provisions, gross		7,228
Mortgage debt		0
Debt to banks		0
Tax payables		0
Contract liabilities		0
Long-term liabilities other than provisions, gross		0
Trade payables		108,137
Tax payables		59,586
Short-term liabilities other than provisions, gross		167,723
Liabilities other than provisions, gross		167,723
LIABILITIES AND EQUITY, GROSS		427,796

Disclosures

1. Disclosure of application of exceptions for micro-undertakings

The micro-undertaking applies the exception concerning filing information about accounting policies

The micro-undertaking applies the exception concerning filing information about number of employees